Cabergoline for preventing ovarian hyperstimulation syndrome in women at risk undergoingin vitro fertilization/intracytoplasmic sperm injection treatment cycles: A randomized controlled study

Background: Ovarian hyperstimulation syndrome (OHSS) is the most serious and potentially life-threatening iatrogenic complication associated with ovarian stimulation during assisted reproductive technology protocols. The aim of this study was to evaluate the role of dopamine agonist as a preventive...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Niyazi Kilic, Özhan Özdemir, Hakan Cevdet Başar, Fadime Demircan, Fırat Ekmez, Oğuz Yücel
Formato:	article
Lenguaje:	EN
Publicado:	Thieme Medical and Scientific Publishers Pvt. Ltd. 2015
Materias:	cabergoline ovarian hyperstimulation vascular endothelial growth factor Medicine R
Acceso en línea:	https://doaj.org/article/eb2843cba3aa46cc95007fbbc7b31399
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:eb2843cba3aa46cc95007fbbc7b31399
record_format	dspace
spelling	oai:doaj.org-article:eb2843cba3aa46cc95007fbbc7b313992021-12-02T16:34:20ZCabergoline for preventing ovarian hyperstimulation syndrome in women at risk undergoingin vitro fertilization/intracytoplasmic sperm injection treatment cycles: A randomized controlled study2231-07702249-446410.4103/2231-0770.165121https://doaj.org/article/eb2843cba3aa46cc95007fbbc7b313992015-10-01T00:00:00Zhttp://www.thieme-connect.de/DOI/DOI?10.4103/2231-0770.165121https://doaj.org/toc/2231-0770https://doaj.org/toc/2249-4464Background: Ovarian hyperstimulation syndrome (OHSS) is the most serious and potentially life-threatening iatrogenic complication associated with ovarian stimulation during assisted reproductive technology protocols. The aim of this study was to evaluate the role of dopamine agonist as a preventive strategy of OHSS in women at high risk in in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) treatment cycles. Methods: Seventy women at risk to develop OHSS undergoing IVF/ICSI treatment cycle were included. The study group received 0.5 mg of cabergoline for 8 days from the day of human chorionic gonadotropin administration in comparison to those who undergo no treatment for the prevention of OHSS. The reduction of the incidence of OHSS was the primary outcome. Results: The actual incidence of OHSS was 8.33% in the cabergoline group and 20.58% in the control group. Thus, the incidence of OHSS was significantly reduced, by almost 60%, in the cabergoline group in comparison with the control group (relative ratios: 0.4, 95% confidence interval: 0.18–0.79). Conclusion: Prophylactic treatment with the dopamine agonist, cabergoline, reduces the incidence of OHSS in women at high risk undergoing IVF/ICSI treatment. However, the effects of cabergoline on important outcomes, namely, live birth, miscarriage, and congenital abnormalities are still uncertain.Niyazi KilicÖzhan ÖzdemirHakan Cevdet BaşarFadime DemircanFırat EkmezOğuz YücelThieme Medical and Scientific Publishers Pvt. Ltd.articlecabergolineovarian hyperstimulationvascular endothelial growth factorMedicineRENAvicenna Journal of Medicine, Vol 05, Iss 04, Pp 123-127 (2015)
institution	DOAJ
collection	DOAJ
language	EN
topic	cabergoline ovarian hyperstimulation vascular endothelial growth factor Medicine R
spellingShingle	cabergoline ovarian hyperstimulation vascular endothelial growth factor Medicine R Niyazi Kilic Özhan Özdemir Hakan Cevdet Başar Fadime Demircan Fırat Ekmez Oğuz Yücel Cabergoline for preventing ovarian hyperstimulation syndrome in women at risk undergoingin vitro fertilization/intracytoplasmic sperm injection treatment cycles: A randomized controlled study
description	Background: Ovarian hyperstimulation syndrome (OHSS) is the most serious and potentially life-threatening iatrogenic complication associated with ovarian stimulation during assisted reproductive technology protocols. The aim of this study was to evaluate the role of dopamine agonist as a preventive strategy of OHSS in women at high risk in in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) treatment cycles. Methods: Seventy women at risk to develop OHSS undergoing IVF/ICSI treatment cycle were included. The study group received 0.5 mg of cabergoline for 8 days from the day of human chorionic gonadotropin administration in comparison to those who undergo no treatment for the prevention of OHSS. The reduction of the incidence of OHSS was the primary outcome. Results: The actual incidence of OHSS was 8.33% in the cabergoline group and 20.58% in the control group. Thus, the incidence of OHSS was significantly reduced, by almost 60%, in the cabergoline group in comparison with the control group (relative ratios: 0.4, 95% confidence interval: 0.18–0.79). Conclusion: Prophylactic treatment with the dopamine agonist, cabergoline, reduces the incidence of OHSS in women at high risk undergoing IVF/ICSI treatment. However, the effects of cabergoline on important outcomes, namely, live birth, miscarriage, and congenital abnormalities are still uncertain.
format	article
author	Niyazi Kilic Özhan Özdemir Hakan Cevdet Başar Fadime Demircan Fırat Ekmez Oğuz Yücel
author_facet	Niyazi Kilic Özhan Özdemir Hakan Cevdet Başar Fadime Demircan Fırat Ekmez Oğuz Yücel
author_sort	Niyazi Kilic
title	Cabergoline for preventing ovarian hyperstimulation syndrome in women at risk undergoingin vitro fertilization/intracytoplasmic sperm injection treatment cycles: A randomized controlled study
title_short	Cabergoline for preventing ovarian hyperstimulation syndrome in women at risk undergoingin vitro fertilization/intracytoplasmic sperm injection treatment cycles: A randomized controlled study
title_full	Cabergoline for preventing ovarian hyperstimulation syndrome in women at risk undergoingin vitro fertilization/intracytoplasmic sperm injection treatment cycles: A randomized controlled study
title_fullStr	Cabergoline for preventing ovarian hyperstimulation syndrome in women at risk undergoingin vitro fertilization/intracytoplasmic sperm injection treatment cycles: A randomized controlled study
title_full_unstemmed	Cabergoline for preventing ovarian hyperstimulation syndrome in women at risk undergoingin vitro fertilization/intracytoplasmic sperm injection treatment cycles: A randomized controlled study
title_sort	cabergoline for preventing ovarian hyperstimulation syndrome in women at risk undergoingin vitro fertilization/intracytoplasmic sperm injection treatment cycles: a randomized controlled study
publisher	Thieme Medical and Scientific Publishers Pvt. Ltd.
publishDate	2015
url	https://doaj.org/article/eb2843cba3aa46cc95007fbbc7b31399
work_keys_str_mv	AT niyazikilic cabergolineforpreventingovarianhyperstimulationsyndromeinwomenatriskundergoinginvitrofertilizationintracytoplasmicsperminjectiontreatmentcyclesarandomizedcontrolledstudy AT ozhanozdemir cabergolineforpreventingovarianhyperstimulationsyndromeinwomenatriskundergoinginvitrofertilizationintracytoplasmicsperminjectiontreatmentcyclesarandomizedcontrolledstudy AT hakancevdetbasar cabergolineforpreventingovarianhyperstimulationsyndromeinwomenatriskundergoinginvitrofertilizationintracytoplasmicsperminjectiontreatmentcyclesarandomizedcontrolledstudy AT fadimedemircan cabergolineforpreventingovarianhyperstimulationsyndromeinwomenatriskundergoinginvitrofertilizationintracytoplasmicsperminjectiontreatmentcyclesarandomizedcontrolledstudy AT fıratekmez cabergolineforpreventingovarianhyperstimulationsyndromeinwomenatriskundergoinginvitrofertilizationintracytoplasmicsperminjectiontreatmentcyclesarandomizedcontrolledstudy AT oguzyucel cabergolineforpreventingovarianhyperstimulationsyndromeinwomenatriskundergoinginvitrofertilizationintracytoplasmicsperminjectiontreatmentcyclesarandomizedcontrolledstudy
_version_	1718383786632151040

Cabergoline for preventing ovarian hyperstimulation syndrome in women at risk undergoingin vitro fertilization/intracytoplasmic sperm injection treatment cycles: A randomized controlled study

Ejemplares similares